Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name DSP107
Synonyms
Therapy Description

DSP107 is a bi-functional trimeric fusion protein that consists of extracellular domains of SIRP alpha and 4-1BBL, which blocks the interaction between CD47 and SIRP alpha, and simultaneously activates the co-stimulatory receptor 4-1BB, potentially activating innate and adaptive immune responses, and inducing cytotoxicity and phagocytosis of tumor cells (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A076; Blood (2020) 136 (Supplement 1): 19-20).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
DSP107 DSP-107|DSP 107|SIRPa-4-1BBL DSP107|SIRPa 4-1BBL DSP107 DSP107 is a bi-functional trimeric fusion protein that consists of extracellular domains of SIRP alpha and 4-1BBL, which blocks the interaction between CD47 and SIRP alpha, and simultaneously activates the co-stimulatory receptor 4-1BB, potentially activating innate and adaptive immune responses, and inducing cytotoxicity and phagocytosis of tumor cells (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A076; Blood (2020) 136 (Supplement 1): 19-20).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04440735 Phase Ib/II Atezolizumab + DSP107 DSP107 A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors Recruiting USA 0


Additional content available in CKB BOOST